Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Thomas R Parr"'
Autor:
Brian D VanScoy, Haley Conde, Nicole Cotroneo, Ian A Critchley, Thomas R Parr, Paul G Ambrose
Publikováno v:
Open Forum Infectious Diseases
Background SPR994 is an orally bioavailable pivoxil hydrobromide prodrug of tebipenem, a novel oral carbapenem with activity against Gram-positive and -negative bacteria currently under development for the treatment of urinary tract infections (UTI).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d01e17fb882efa5913f5e8692a70b2
http://europepmc.org/articles/PMC8644764
http://europepmc.org/articles/PMC8644764
Autor:
Troy Lister, Paul R. Rhomberg, Thomas R. Parr, Mariana Castanheira, Nicole Cotroneo, Rodrigo E. Mendes
Publikováno v:
Antimicrob Agents Chemother
The activities of azithromycin, fusidic acid, vancomycin, doxycycline, and minocycline were evaluated alone and in combination with SPR741. A total of 202 Escherichia coli and 221 Klebsiella pneumoniae isolates were selected, and they included a geno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::408c473bad37f79cd2c8f75886de4bbb
https://europepmc.org/articles/PMC7927843/
https://europepmc.org/articles/PMC7927843/
Publikováno v:
Expert Review of Anti-infective Therapy. 16:513-522
Infections caused by antibiotic-resistant pathogens, particularly Gram-negative bacteria, have become increasingly challenging to successfully treat. The beta-lactam antibiotic subclass, the carbapenems, have proven valuable for the treatment of such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f24f243a6c5815d7d573410c461ca6f6
https://doi.org/10.1080/14787210.2018.1496821
https://doi.org/10.1080/14787210.2018.1496821
Autor:
Aileen Rubio, Evelyne Lacasse, François Malouin, Eric Brouillette, Audrey Larose, Thomas R. Parr
Tebipenem (SPR859) is the microbiologically active form of SPR994 (tebipenem-pivoxil), an orally available carbapenem with activity against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae . Measurement of the relative binding of SP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48d306d8a5f0b755eab97c70385c40b4
https://europepmc.org/articles/PMC6437484/
https://europepmc.org/articles/PMC6437484/
Autor:
Laura McEntee, William W. Hope, Aaron Dane, Akash Jain, Jennifer Unsworth, Ian A. Critchley, Nicola Farrington, Shampa Das, Nicole Cotroneo, David Melnick, Adam Johnson, Thomas R. Parr, Paul G. Ambrose
Publikováno v:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Tebipenem pivoxil HBr (TBPM-PI-HBr) is a novel orally bioavailable carbapenem. The active moiety is tebipenem. Tebipenem pivoxil is licensed for use in Japan in children with ear, nose, and throat infections and respiratory infections. The HBr salt w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f25a211d6eb616e7e089aac4c6af447
https://pubmed.ncbi.nlm.nih.gov/31109982
https://pubmed.ncbi.nlm.nih.gov/31109982
Autor:
Gerard D. Wright, Eric Brouillette, J. Andrew N. Alexander, Marija Vuckovic, Eric D. Brown, Samarendra N. Maiti, Dustin T. King, Andrew M. King, Natalie C. J. Strynadka, Abdelhamid Asli, Shawn French, François Malouin, Thomas R. Parr
Publikováno v:
ACS Chemical Biology. 11:864-868
Avibactam is a diazabicyclooctane β-lactamase inhibitor possessing outstanding but incomplete efficacy against multidrug-resistant Gram-negative pathogens in combination with β-lactam antibiotics. Significant pharmaceutical investment in generating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6035bcd8a4a45a55aa9d8b304da1445
https://doi.org/10.1021/acschembio.5b00944
https://doi.org/10.1021/acschembio.5b00944
Autor:
Thomas R. Parr, Paul G. Ambrose, Brian VanScoy, Steven Fikes, Christopher M. Rubino, Ian A. Critchley, Sujata M. Bhavnani, Nicole Cotroneo
Publikováno v:
Open Forum Infectious Diseases
Background Tebipenem pivoxil hydrobromide (tebipenem HBr), an orally (PO) bioavailable prodrug of tebipenem, is a carbapenem with broad-spectrum activity against Gram-positive and -negative bacteria that is being developed for the treatment of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb3abcf935a2a5e72fe92be2b6fcfa5
https://doi.org/10.1093/ofid/ofaa439.1487
https://doi.org/10.1093/ofid/ofaa439.1487
Autor:
Nicole Cotroneo, Thomas R. Parr, Sujata M. Bhavnani, Paul G. Ambrose, Ana I Caranco, Nikolas J Onufrak, Haley Conde, Ian A. Critchley, Brian VanScoy
Publikováno v:
Open Forum Infectious Diseases
Background SPR859 (tebipenem) is the active form of the orally bioavailable prodrug SPR994. Tebipenem is an oral carbapenem with a broad-spectrum activity against Gram-positive and -negative bacteria. SPR994 is being developed as an oral option for t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0ee34ef29603f893fa0e8ebc9e7c5eb
http://europepmc.org/articles/PMC6810112
http://europepmc.org/articles/PMC6810112
Publikováno v:
Medicinal Chemistry Reviews ISBN: 9780996293235
Medicinal Chemistry Reviews
Medicinal Chemistry Reviews
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adcbd007ab70f46faaef3aca8dd590ae
https://doi.org/10.29200/acsmedchemrev-v51.ch15
https://doi.org/10.29200/acsmedchemrev-v51.ch15
Publikováno v:
Current opinion in microbiology. 33
Infections caused by antibiotic-resistant pathogens, particularly Gram-negative bacteria, represent significant treatment challenges for physicians resulting in high rates of morbidity and mortality. The outer membrane of Gram-negative bacteria acts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c00d5ce95693695cdaaf9f3016feff4
https://pubmed.ncbi.nlm.nih.gov/27232956
https://pubmed.ncbi.nlm.nih.gov/27232956